Published

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuropharmacology
Date: 2022-11-15
Source: PubMed
DOI: 10.1016/j.neuropharm.2022.109214
PubMed: 35973601

Authors

Belouin SJ Averill LA Henningfield JE Xenakis SN Donato I Grob CS Berger A Magar V Danforth AL Anderson BT

Watch author

Derived topics and classifications

psilocybin Review Article Review Article

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.2022-11-15

Related papers

Psychedelic Therapy for DepressionUnknown journal · 2026-08-11 Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01 Assessing Canadian Policy Readiness for Psychedelic-Assisted Therapy in Cancer CareUnknown journal · 2026-08-17 Defining 'psychedelic'.Journal of psychopharmacology (Oxford, England) · 2026-08-17 Ayahuasca and Salvia divinorum as contrasting modes of consciousness reorganization: Implications for psychedelic-assisted psychotherapyJournal of Psychedelic Studies · 2026-08-13 Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-02 Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.Drugs · 2026-08-01 A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study.The International journal on drug policy · 2026-08-01